Clinical Trial Objectives, page-39

Same here. I see Sirtex as a company with an excellent and profitable track record.

A successful trial result would have paved way for a newer product (ergo, increase in stock price based on new valuation). The failed test result should only result in a devaluation that subtracts money paid for the clinical trials. I concede that there was some amount invested into the company in anticipation of successful trial result. However, I believe that the current devaluation does not correctly reflect the underlying value of Sirtex, which has been doing just fine for a long time.